Summary: Researchers have developed CAPPSID, a new cancer therapy that coordinates bacteria and viruses to infiltrate and eliminate tumors. The approach conceals an oncolytic virus inside tumor-seeking Salmonella typhimurium, allowing the virus to evade immune detection and reach cancer sites. Once inside cancer cells, the bacteria release the viral genome so the virus can replicate and spread through the tumor. Built-in safety features make the virus dependent on a bacterial enzyme for maturation, reducing the risk of uncontrolled spread.
Key Facts:
- Dual attack strategy: Combines tumor-homing bacteria with cancer-killing viruses to leverage the strengths of both microbes.
- Immune evasion: Bacteria shield the viral genome from circulating antibodies, enabling delivery to tumors even in immune animals.
- Safety controls: Viral maturation is engineered to require a bacterial protease, limiting productive infection to tumor sites where the bacteria reside.
Source: Columbia University
Overview
A team led by Tal Danino at Columbia Engineering has designed CAPPSID (Coordinated Activity of Prokaryote and Picornavirus for Safe Intracellular Delivery), a platform that engineers cooperation between bacteria and an oncolytic virus to treat solid tumors. Working with virology experts including Charles M. Rice, the group reports a system in which Salmonella typhimurium transports and delivers the RNA genome of an oncolytic virus into cancer cells, protects that genome from neutralizing antibodies in circulation, and enables controlled viral maturation only in the tumor microenvironment.
CAPPSID builds on two complementary microbial behaviors: bacteria preferentially colonize the low-oxygen, nutrient-rich cores of many tumors, while oncolytic viruses preferentially infect and kill cancer cells. By combining these properties, the platform aims to deliver a potent antiviral payload directly inside tumors, overcome pre-existing immunity, and confine viral activity to tumor tissue through synthetic interdependence between the microbes.
Sneaking past the immune system
A major limitation of oncolytic virus therapies is neutralizing antibodies in patients who have prior exposure to the same virus or related vaccines. CAPPSID addresses this by packaging the viral RNA inside engineered Salmonella. The bacteria act as a protective carrier, shielding the viral genome from circulating antibodies and transporting it to tumor sites where the bacteria preferentially accumulate.
This strategy is particularly relevant for viruses that commonly circulate in humans and for patients who have existing immunity. By using bacteria as a delivery vehicle, the therapeutic viral genome can bypass immune neutralization, enter cancer cells, and initiate replication where it is needed most.
Targeting the tumor
The bacterial component of the system, Salmonella typhimurium, naturally homes to and grows within tumor tissue. The engineered bacteria invade cancer cells and then lyse, releasing the viral genome directly into the interior of the tumor. Once released, the viral RNA can replicate and spread from cell to cell, amplifying the therapeutic effect throughout the tumor mass.
By exploiting the bacteria’s tumor-homing behavior and the virus’s ability to replicate selectively in cancer cells, CAPPSID overcomes penetration challenges that have limited single-microbe therapies and enables deeper, more uniform distribution of the oncolytic agent within solid tumors.
Safeguarding against runaway infections
Safety is a central design principle for CAPPSID. To prevent the engineered virus from spreading beyond the tumor, the researchers made viral maturation dependent on a bacterial protease that the virus cannot obtain elsewhere in the body. Because the bacteria remain localized to the tumor environment, productive virion formation can only occur in the immediate vicinity of those bacteria.
This synthetic dependence provides a layered safeguard: even if viral genomes escape the tumor, they should be unable to mature into infectious particles in healthy tissue. The team emphasizes that such safety-oriented designs are essential for translating living microbial therapies into clinical use.
Further research and clinical applications
The study, validated in mouse models, represents an early but important step toward clinical translation of multi-organism cancer therapies. The investigators are extending their work across additional tumor types and mouse models, experimenting with different viruses and therapeutic payloads, and assembling a toolkit of engineered viral therapies that can sense and respond to cellular conditions.
They are also evaluating how CAPPSID could be combined with bacterial strains that already have established safety records in human clinical trials. The research team has filed a patent application covering aspects of this technology and is pursuing paths toward eventual clinical testing.
About this research
Author: Michele Hoos
Source: Columbia University
Contact: Michele Hoos – Columbia University
Image credit: Neuroscience News
Original research: Open access. “Engineered bacteria launch and control an oncolytic virus” by Tal Danino et al., published in Nature Biomedical Engineering.
Abstract
Engineered bacteria launch and control an oncolytic virus
The selective replication of bacteria and viruses in tumors motivated the design of a cooperative microbial therapy. Here, Salmonella typhimurium bacteria transcribe and deliver the RNA genome of Senecavirus A into host tumor cells, launching a potent oncolytic infection. Encapsidated by bacteria, the viral genome can bypass circulating antiviral antibodies and initiate replication and spread within immune animals. Finally, the virus was engineered to require a bacterially delivered protease for virion maturation, demonstrating bacterial control over viral propagation. Together, this platform—termed CAPPSID—extends bacterially delivered therapeutics to viral genomes and shows how a consortium of microbes can achieve a coordinated therapeutic outcome.